Status:
COMPLETED
Precoce Medical Care by the Mobil Support for Patients With Glioblastoma
Lead Sponsor:
Institut du Cancer de Montpellier - Val d'Aurelle
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Most patients with glioblastoma have impaired cognitive function, autonomy, and quality of life. This clinical situation, combined with a limited life expectancy, makes the preservation of quality of...
Detailed Description
glioblastomas are the most common primary malignant tumours of the central nervous system.They represent about 2000 new cases per year in France. Despite active treatments including surgery, radiothe...
Eligibility Criteria
Inclusion
- Adult patient ( ≥ 18 years),
- Histological diagnosis of Glioblastoma
- Oncology caret at ICM (regardless of treatment: Stupp protocol, chemotherapy alone, targeted therapy, etc.);
- Patient consent signed after informed information.
Exclusion
- Patient unable to consent to the study
- Major impairment of the general health : performance status OMS =4;
- Patient not affiliated with a French social security
Key Trial Info
Start Date :
May 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 15 2022
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04516733
Start Date
May 10 2019
End Date
February 15 2022
Last Update
March 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ICM Val d'Aurelle
Montpellier, France, 34298